Highest-materiality recent filing
Immix Biopharma prices $150M public offering of 16.8M shares at $8.94
Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.
Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR
All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).
Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026
Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.
Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026
NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10
19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.
Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board
Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.
Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial
$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.
Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella
On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.
Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share
Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.
Immix Biopharma raises $10M via private placement; appoints new director
Gross proceeds of ~$10M from sale of 3.24M shares at $1.94/share and 1.91M pre-funded warrants at $1.9399.
Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma
In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.
100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.
Immix Biopharma reports IMX-110 50% response rate in STS mouse study, beating standard of care
IMX-110 as monotherapy achieved 50% response rate in first-line-therapy-resistant STS mouse study, vs 0% for doxorubicin.
Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma
FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.
Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds
IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.
Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board
Max materiality 0.85 · Median 0.50 · Most common event other_material